HC Wainwright Reaffirms Neutral Rating for Kezar Life Sciences (NASDAQ:KZR)

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $0.79 on Wednesday. Kezar Life Sciences has a 52-week low of $0.52 and a 52-week high of $1.19. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. The firm has a market cap of $57.57 million, a price-to-earnings ratio of -0.56 and a beta of 0.20. The business’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.70.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Analysts forecast that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors have recently modified their holdings of the business. Affinity Asset Advisors LLC bought a new position in shares of Kezar Life Sciences during the first quarter valued at approximately $1,588,000. Stonepine Capital Management LLC bought a new stake in Kezar Life Sciences in the second quarter valued at $630,000. Acadian Asset Management LLC boosted its holdings in shares of Kezar Life Sciences by 42.5% during the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after acquiring an additional 534,203 shares during the period. Acuitas Investments LLC grew its position in shares of Kezar Life Sciences by 42.8% during the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after acquiring an additional 295,956 shares during the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Kezar Life Sciences in the 1st quarter worth about $114,000. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.